Receipt date: 03/13/2006

PTO/SB/08B (08-03) Approved for use through 07/31/2006, OMB 0651-0031

Substitute for form 1449/PTO			PTO	Complete if Known		
	INFORMATION DISCLOSURE			Application Number	10/541,115	
STATEMENT BY APPLICANT				Filing Date	December 23, 2003	
(Use as many sheets as necessary)				First Named Inventor	Jingwu Z. Zang	
	(Use as	many sn	eets as necessary)	Group Art Unit	Not yet assigned	
				Examiner Name	Not yet assigned	
Sheet	1	of	1	Attorney Docket Number	05627.0008.PCUS01	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTIES), tide of the article (when appropriate), tide of the item (book, magazine, journal, serial, symposume, entable, etc.), date, page(s), volume-assue number(s), publisher city and/or country where published	T ²
	Cl	Tejada-Simon, M., et al., "Cross-Reactivity with Myelin Basic Protein and Human Herpesvirus-6 in Multiple Sclerosis," Annals of Neurology, Vol. 53, No. 2, pp. 189-197 (2003)	
	C2	Stinissen, P., et al., "γδ T Cell Responses to Activated T Cells In Multiple Sclerosis Patients Induced by T Cell Vaccination," Journal of Neuroimmunology, No. 87, pp. 94-104 (1998)	
	C3	Stinissen, P., et al., "Vaccination with Autoreactive T Cell Clones in Multiple Sclerosis: Overview of Immunological and Clinical Data," Journal of Neuroscience Research, Vol. 45, No, 4, pp. 500-511 (1996)	
	C4	Zhang, J., et al., "T Cell Vaccination: Clinical Application in Autoimmune Diseases," Journal of Molecular Medicine, Vol. 74, No. 11, pp. 653-662 (1996)	
	C5	Zhang, J., et al., "MHC-Restricted Depletion of Human Myelin Basic Protein-Reactive T Cells by T Cell Vaccination," Science, Vol. 261, pp. 1451-1454 (1993)	
	C6	Supplementary European Search Report of EP 03 80 0185 dated January 9, 2006.	
			E
			1

Examiner	/Amy Juedes/	Date	02/13/2009
Signature		Considered	02/13/2009

^{**}PRIMATINE*** II. The initial if reference considered, whether or not ciusion is in conformance with MFPF 660. Down line through ciusion if not in conformance and not considered, bright copy of this form with next communication to applicant.

PRIMATINE II. The next communication is applicant.

**Applicant's tumper, exclaim designation mather (optional). **Projection is to place a check mark here if English Isaguage Translation is attached.

**This collection of information is required by 37 CRF 108. The information is required to dozation or retain as benefit by the public which is to file (ond by the USPTO to process) an application Confidentiality is sported by 37 CRF 108. The information is required to dozation or retain as benefit by the public which is to file (ond by the USPTO to process) an application Confidentiality is sported by 37 CRF 122 and 37 CRF 11. This collection is emitted to take 2 boars to complete, including gallering, preparing, and submitting the completed applications from to the USPTO. This will very depending upon the individual case. Any comment on the arround of true for the complete application from the formation of the complete application from the dependence of the complete applications. The complete application from the arround of true for the complete applications of the complete application Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.